

Table S1. Primers used in this study.

Description	Direction	Sequence
JEV Nakayama strain prM-E cloning into pcDNA3.1	Forward	5'-CCG <u>G</u> AATT <u>C</u> ACC <u>A</u> TGG <u>A</u> AGG <u>C</u> TAAT <u>C</u> ATGTGG-3'
	Reverse	5'-GCC <u>C</u> TC <u>G</u> AG <u>T</u> TAAG <u>C</u> AT <u>G</u> CAC <u>A</u> TGG <u>C</u> G-3'
JEV Beijing-1 strain prM-E cloning into pcDNA3.1	Forward	5'-CCG <u>G</u> AATT <u>C</u> ACC <u>A</u> TGG <u>A</u> AGG <u>C</u> TAAT <u>C</u> ATGTGG-3'
	Reverse	5'-GCT <u>AC</u> CA <u>A</u> T <u>T</u> GC <u>A</u> T <u>G</u> CT <u>T</u> A- <u>A</u> CT <u>G</u> AG <u>G</u> CC-3'
JEV P3 strain prM-E cloning into pcDNA3.1	Forward	5'-CCG <u>G</u> AATT <u>C</u> ACC <u>A</u> TGG <u>A</u> AGG <u>C</u> TAAT <u>C</u> ATGTGG-3'
	Reverse	5'-GCG <u>AC</u> CA <u>A</u> T <u>T</u> GC <u>A</u> T <u>G</u> CT <u>T</u> A- <u>A</u> CT <u>G</u> AG <u>G</u> CC-3'
DENV-2 NGC strain prM-E cloning into pcDNA3.1	Forward	5'-CGG <u>G</u> AT <u>A</u> T <u>C</u> ACC <u>A</u> T <u>G</u> AAC <u>C</u> AG <u>G</u> AC <u>G</u> C <u>A</u> ACT-3'
	Reverse	5'-GCC <u>C</u> TC <u>G</u> AG <u>T</u> TA <u>G</u> GC <u>C</u> AC <u>A</u> T <u>A</u> CT <u>C</u> -3'
Sequence primer designed on CMV promoter	Forward	5'-GGCGTGTACGGTGGGAGGTC-3'
JEV prM-E sequence primer 1	Forward	5'-AGCATT <u>C</u> CA <u>A</u> G <u>A</u> C <u>T</u> AG <u>T</u> AG <u>G</u> AG <u>A</u> T <u>C</u> CG <u>T</u> -3'
JEV prM-E sequence primer 2	Forward	5'-GG <u>C</u> T <u>C</u> AC <u>AG</u> GA <u>AG</u> GA <u>GG</u> AG <u>GC</u> -3'
JEV prM-E sequence primer 3	Reverse	5'-AG <u>T</u> CG <u>T</u> G <u>AA</u> AG <u>G</u> CT <u>T</u> GC <u>C</u> -3'
DENV-2 prM-E sequence primer 1	Forward	5'-GC <u>A</u> T <u>AG</u> GA <u>AT</u> AT <u>C</u> AA <u>A</u> T <u>A</u> G <u>A</u> -3'
DENV-2 prM-E sequence primer 2	Forward	5'-GCT <u>T</u> CC <u>G</u> AG <u>A</u> AC <u>GG</u> GC <u>CT</u> CG-3'
DENV-2 prM-E sequence primer 3	Forward	5'-AAC <u>T</u> CC <u>A</u> TT <u>CG</u> AG <u>A</u> CG <u>A</u> C <u>G</u> -3'
JEV Nakayama G106V introduction	Forward	5'-GT <u>A</u> CT <u>TT</u> CG <u>GG</u> A <u>AG</u> GG <u>A</u> AG <u>C</u> ATT <u>G</u> AC-3'
	Reverse	5'-AC <u>A</u> T <u>CC</u> GT <u>T</u> G <u>CC</u> CC <u>AC</u> CC <u>AC</u> GA <u>T</u> CA <u>G</u> -3'
JEV Nakayama L107F introduction	Forward	5'-GG <u>A</u> TT <u>TT</u> CG <u>GG</u> A <u>AG</u> GG <u>A</u> AG <u>C</u> ATT <u>G</u> AC-3'
	Reverse	5'-AC <u>A</u> T <u>CC</u> GT <u>T</u> G <u>CC</u> CC <u>AC</u> CC <u>AC</u> GA <u>T</u> CA <u>G</u> -3'
JEV Nakayama G106V/L107F introduction	Forward	5'-GT <u>A</u> TT <u>TT</u> CG <u>GG</u> A <u>AG</u> GG <u>A</u> AG <u>C</u> ATT <u>G</u> AC-3'
	Reverse	5'-AC <u>A</u> T <u>CC</u> GT <u>T</u> G <u>CC</u> CC <u>AC</u> CC <u>AC</u> GA <u>T</u> CA <u>G</u> -3'
JEV Beijing-1 G106V introduction	Forward	5'-GT <u>A</u> CT <u>TT</u> CG <u>GG</u> A <u>AG</u> GG <u>A</u> AG <u>C</u> ATT <u>G</u> AC-3'
	Reverse	5'-GAT <u>CG</u> T <u>GG</u> GT <u>GG</u> GA <u>AC</u> GG <u>A</u> GT <u>T</u> -3'
JEV P3 G106V introduction	Forward	5'-GT <u>A</u> CT <u>TT</u> CG <u>GG</u> A <u>AG</u> GG <u>A</u> AG <u>C</u> ATT <u>G</u> AC-3'
	Reverse	5'-GAT <u>CG</u> T <u>GG</u> GT <u>GG</u> GA <u>AC</u> GG <u>A</u> GT <u>T</u> -3'
DENV-2 G106V introduction	Forward	5'-GT <u>A</u> TT <u>TT</u> CG <u>GG</u> A <u>AG</u> GG <u>A</u> AG <u>C</u> ATT <u>G</u> AC-3'
	Reverse	5'-AC <u>A</u> T <u>CC</u> AT <u>T</u> CC <u>CC</u> AT <u>C</u> CT <u>T</u> GT <u>CC</u> -3'

Underline: Restriction enzyme site.




Figure S1. Determination of 50% lethal dose. A serially diluted JEV P3 strain was inoculated intraperitoneally into six or seven 6-week-old BALB/c mice to determine the 50% lethal dose (LD₅₀). The mice were monitored for 20 days. Mice were humanely euthanized if they showed apparent symptoms or a decrease of >20% in their initial body weight. The estimated LD₅₀ was 1.4 × 10⁵ focus forming unit (FFU).